Lupus Program News Today

Karen Costenbader, MD, discusses how early intervention with belimumab in patients with lupus significantly reduces disease flares and prevents irreversible organ damage.

Rates of significant disease reactivation were similar more than 1 year after randomization for patients assigned to mycophenolate mofetil (MMF) withdrawal or MMF maintenance.

/PRNewswire/ -- Lupus is a complicated and debilitating autoimmune disease, affecting millions of people across the globe. Yet, lupus drug development lags...

The American Autoimmune Related Disease Association (AARDA) hosted the 15th Noel Rose Scientific Colloquium on May 1, 2021, bringing together high-level researc

Read More "There is a lot about lupus that is still a conundrum to us," said Dr. Karen H. Costenbader, a professor of medicine at Harvard Medical School and director of the Lupus Program at Brigham and Womens Hospital in Boston. "Its treatable, but it can still be very painful and challenging to overcome," said Costenbader, who is also chair of the Lupus Foundation of Americas Medical-Scientific Advisory Council. May 10 is World Lupus Day, and we recently caught up with Costenbader to learn mo...

WireImage Lupus is unpredictable, triggering different symptoms in different patients. A chronic illness, it can even attack many different parts of the body. The condition is an autoimmune disease, which means that a person’s immune system—the body system that usually fights infections—attacks healthy tissue instead. It can cause inflammation and pain anywhere in a patient’s body. Because the illness can look different in every patient, it can go undetected and undiagnosed for years. ...

World Lupus Federation Global Survey of People with Lupus Finds Half of Respondents Experienced a Decrease in Access to Healthcare During COVID-19 Pandemic earlier than the general population WASHINGTON, April 21, 2021 /PRNewswire/ -- In a new global survey, more than 6,100 people with lupus from over 85 countries shared their recent experiences of the COVID-19 pandemic and their views of the COVID-19 vaccines. Half (50%) of the survey participants reported decreased access to at least one aspe...

Lupus Foundation of America Congratulates Aurinia Pharmaceuticals on FDA Approval of Lupkynis™ (voclosporin) to Treat Lupus Nephritis First FDA-approved oral treatment for lupus nephritis represents a significant milestone for people living with lupus-related kidney disease, a leading cause of disability and mortality in lupus News provided by Share this article Share this article WASHINGTON, Jan. 22, 2021 /PRNewswire/ --  For the second time in less than two months, the U.S. Food and Drug ...

Lupus Foundation of America Sees Big Win with FDA Approval of Benlysta for Lupus Nephritis News provided by Share this article Share this article WASHINGTON, Dec. 17, 2020 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved Benlysta to treat lupus nephritis (lupus-related kidney disease) in adults. The approval is for both the intravenous and subcutaneous formulations. The decision makes Benlysta the first lupus therapy authorized to treat this potentially life-threatening ...